{"id":415,"date":"2023-08-25T13:57:15","date_gmt":"2023-08-25T05:57:15","guid":{"rendered":"https:\/\/consulting-hmk.com\/?p=415"},"modified":"2024-01-18T09:56:47","modified_gmt":"2024-01-18T01:56:47","slug":"retagliptin-phosphate-tablets-approved-for-marketing-by-china-nmpa","status":"publish","type":"post","link":"https:\/\/www.consulting-hmk.com\/fr\/comprimes-de-phosphate-de-retagliptine-approuves-pour-la-commercialisation-par-la-china-nmpa\/","title":{"rendered":"Comprim\u00e9s de phosphate de r\u00e9tagliptine : autorisation de mise sur le march\u00e9 par l'APMN de Chine"},"content":{"rendered":"<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">\u00a0 \u00a0 \u00a0 R\u00e9cemment, le m\u00e9dicament innovant de cat\u00e9gorie 1 Retagliptin Phosphate Tablets (nom commercial chinois : \u745e\u6cfd\u5510) de Jiangsu Hengrui Pharmaceuticals Co., Ltd. a \u00e9t\u00e9 approuv\u00e9 par l'APMN de Chine. Il est indiqu\u00e9 pour am\u00e9liorer le contr\u00f4le de la glyc\u00e9mie chez les patients adultes atteints de diab\u00e8te de type 2.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><img decoding=\"async\" loading=\"lazy\" class=\"wp-image-395 aligncenter\" title=\"Comprim\u00e9s de phosphate de r\u00e9tagliptine : autorisation de mise sur le march\u00e9 par l&#039;APMN de Chine\" src=\"https:\/\/consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-300x168.jpg\" alt=\"Comprim\u00e9s de phosphate de r\u00e9tagliptine : autorisation de mise sur le march\u00e9 par l&#039;APMN de Chine\" width=\"568\" height=\"318\" srcset=\"https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-300x168.jpg 300w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-1024x574.jpg 1024w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-768x430.jpg 768w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-1536x861.jpg 1536w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-2048x1148.jpg 2048w\" sizes=\"(max-width: 568px) 100vw, 568px\" \/><\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">Le phosphate de r\u00e9tagliptine est un inhibiteur de la dipeptidyl peptidase 4 (DPP-4) qui inhibe la DPP-4 pour hydrolyser l'hormone incr\u00e9tine, augmentant ainsi la concentration plasmatique du peptide-1 de type glucagon actif (GLP-1) et du polypeptide de type insuline d\u00e9pendant du glucose (GIP). Il augmente la lib\u00e9ration d'insuline de mani\u00e8re d\u00e9pendante du glucose et diminue le glucagon pour r\u00e9duire la glyc\u00e9mie. La mise sur le march\u00e9 de ce m\u00e9dicament offre de nouvelles options th\u00e9rapeutiques aux patients adultes atteints de diab\u00e8te de type 2.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>R\u00e9cemment, le m\u00e9dicament innovant de cat\u00e9gorie 1 Retagliptin Phosphate Tablets de Jiangsu Hengrui Pharmaceuticals Co., Ltd. a \u00e9t\u00e9 approuv\u00e9 par l'APMN de Chine. Il est indiqu\u00e9 pour am\u00e9liorer le contr\u00f4le de la glyc\u00e9mie chez les patients adultes atteints de diab\u00e8te de type 2.<\/p>","protected":false},"author":4,"featured_media":416,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[70],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/posts\/415"}],"collection":[{"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/comments?post=415"}],"version-history":[{"count":0,"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/posts\/415\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/media\/416"}],"wp:attachment":[{"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/media?parent=415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/categories?post=415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/tags?post=415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}